Cargando…

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

BACKGROUND: Emerging data support the use of thymidine kinase 1 (TK1) activity as a prognostic marker and for monitoring of response in breast cancer (BC). The long-term prognostic value of TK1 kinetics during neoadjuvant chemotherapy is unclear, which this study aimed to elucidate. METHODS: Materia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matikas, A., Wang, K., Lagoudaki, E., Acs, B., Zerdes, I., Hartman, J., Azavedo, E., Bjöhle, J., Carlsson, L., Einbeigi, Z., Hedenfalk, I., Hellström, M., Lekberg, T., Loman, N., Saracco, A., von Wachenfeldt, A., Rotstein, S., Bergqvist, M., Bergh, J., Hatschek, T., Foukakis, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957142/ https://www.ncbi.nlm.nih.gov/pubmed/33714010 http://dx.doi.org/10.1016/j.esmoop.2021.100076

Ejemplares similares

Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
por: Kimbung, Siker, et al.
Publicado: (2017)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
por: Palazon, Asis, et al.
Publicado: (2017)

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
por: Tobin, N. P., et al.
Publicado: (2015)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
por: Kimbung, Siker, et al.
Publicado: (2015)

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
por: Einbeigi, Z., et al.
Publicado: (2008)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
por: von Stedingk, Hans, et al.
Publicado: (2014)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

THYMIDINE TRIPHOSPHATE SYNTHESIS IN TETRAHYMENA : I. Studies on Thymidine Kinase
por: Shoup, G. D., et al.
Publicado: (1966)

Pathways of thymidine hypermodification
por: Lee, Yan-Jiun, et al.
Publicado: (2021)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

3'-Amino thymidine affinity matrix for the purification of herpes simplex virus thymidine kinase.
por: Tung, P. P., et al.
Publicado: (1996)

THYMIDINE DEGRADATION PRODUCTS IN PLANT TISSUES LABELED WITH TRITIATED THYMIDINE
por: Takats, S. T., et al.
Publicado: (1963)

INDUCIBILITY OF THYMIDINE KINASE BY THYMIDINE AS A FUNCTION OF INTERPHASE STAGE
por: Hotta, Yasuo, et al.
Publicado: (1965)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Use of thymidine analogues to indicate vascular perfusion in tumours
por: Begg, A C, et al.
Publicado: (2000)

Mammographic density and molecular subtypes of breast cancer
por: Eriksson, L, et al.
Publicado: (2012)

Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer
por: Carlsson, Lena, et al.
Publicado: (2009)

Thymidine kinase in breast cancer.
por: Robertson, J. F., et al.
Publicado: (1990)

A hypothesis-generating search for new genetic breast cancer syndromes - a national study in 803 Swedish families
por: von Wachenfeldt, Anna, et al.
Publicado: (2007)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
por: Wei, Qiong, et al.
Publicado: (2015)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
por: Larsson, Anna-Maria, et al.
Publicado: (2020)

Serum thymidine kinase in acute leukaemia.
por: Hagberg, H., et al.
Publicado: (1984)

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro
por: Bijnsdorp, I.V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6j23vt1v3hv742i33f9pi3n2po